Psychiatric symptom differences in people with schizophrenia associated with substantial lifetime substance use but no current substance use disorder
暂无分享,去创建一个
D. Kelly | H. Wehring | Kimberly R. Warren | S. Feldman | M. Huestis | D. Gorelick | M. Koola | R. Mcmahon | Jared Linthicum | Fang Liu
[1] R. Conley,et al. Rimonabant for neurocognition in schizophrenia: A 16-week double blind randomized placebo controlled trial , 2012, Schizophrenia Research.
[2] L. Dixon,et al. Time to discontinuation of first- and second-generation antipsychotic medications in the treatment of schizophrenia , 2011, Schizophrenia Research.
[3] R. Conley,et al. Effects of the Cannabinoid-1 Receptor Antagonist Rimonabant on Psychiatric Symptoms in Overweight People With Schizophrenia: A Randomized, Double-Blind, Pilot Study , 2011, Journal of clinical psychopharmacology.
[4] Jean Addington,et al. Reliability and validity of a depression rating scale for schizophrenics , 1991, Schizophrenia Research.
[5] A T McLellan,et al. An Improved Diagnostic Evaluation Instrument for Substance Abuse Patients: The Addiction Severity Index , 1980, The Journal of nervous and mental disease.
[6] Julie Kreyenbuhl,et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. , 2010, Schizophrenia bulletin.